- 13 April 2020Portfolio NewsSutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
- 7 April 2020Portfolio NewsBicycle Therapeutics Announces Pipeline Progress Update
- 31 March 2020Portfolio NewsSV Health Investors Announces Licensing and Research Collaboration between Sitryx and Lilly to Discover and Develop New Immunometabolic Medicines
- 26 March 2020Portfolio NewsSutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
- 16 March 2020Portfolio NewsAVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
- 12 March 2020Portfolio NewsSutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
- 10 March 2020Portfolio NewsBicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
- 9 March 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
- 9 March 2020Portfolio NewsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
- 4 March 2020Portfolio NewsSV Health Investors joins Xilio Therapeutics’ $100.5 million Series B financing - proceeds will advance XTX201 and XTX101 into the clinic while expanding Xilio’s cytokine pipeline
- 2 March 2020Portfolio NewsEvelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
- 2 March 2020Portfolio NewsAkrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing